Early Dementia Detection: New Blood Biomarker Study
- A new multicenter study spearheaded by UCLA researchers suggests a potential breakthrough in early dementia detection.
- The study focuses on placental growth factor (PlGF), a protein vital for blood vessel formation.
- Cerebral small vessel disease (CSVD), a major contributor to cognitive decline, is often linked to dysfunctional cells lining brain blood vessels.
Breakthrough news in early dementia detection! A UCLA-led study reveals that a simple blood test measuring placental growth factor (PlGF) could identify early signs of cognitive impairment before mris. This innovative blood test offers a cost-effective alternative to traditional methods, perhaps revolutionizing the way we diagnose and treat dementia, and could become a vital tool for identifying those at risk for vascular brain injury. the study,published in Alzheimer’s & Dementia,indicates elevated PlGF levels may signal vascular issues linked to cognitive decline,offering the ability to screen younger individuals,allowing for earlier interventions. The MarkVCID consortium conducted the study, involving older adults, MRIs, and blood tests. News Directory 3 brings you the latest on this promising research. Discover what’s next in cognitive health advancements.
Blood Test May Detect Early signs of Dementia, Cognitive Impairment
A new multicenter study spearheaded by UCLA researchers suggests a potential breakthrough in early dementia detection. Instead of relying on MRIs to assess late-stage biological markers, a simple blood test could identify changes much earlier in the process.
The study focuses on placental growth factor (PlGF), a protein vital for blood vessel formation. Researchers found that PlGF levels in plasma might serve as a biomarker for screening and monitoring cognitive impairment and dementia.The findings, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, analyzed data from a large patient group with varying vascular risk profiles and cognitive abilities.
Cerebral small vessel disease (CSVD), a major contributor to cognitive decline, is often linked to dysfunctional cells lining brain blood vessels. These “leaky” vessels allow fluids and inflammatory molecules to seep into brain tissue. While CSVD is typically diagnosed via MRI, the resulting white matter hyperintensities (WMH) are late indicators of vascular brain injury.
The research team investigated the relationships between PlGF levels, white matter free water (FW) – a sensitive MRI measure of fluid accumulation – WMH, and cognitive assessment scores.The results indicated that elevated PlGF increases vascular permeability, leading to fluid accumulation, WMH development, and subsequent cognitive impairment.
Kyle Kern, a vascular neurologist at UCLA Health, believes PlGF could be a cost-effective screening tool for identifying at-risk patients before cognitive decline becomes apparent. “As a biomarker for cerebral small vessel disease and the vascular contributions to cognitive impairment and dementia (VCID), PlGF could be used as a cost-effective screening tool for identifying patients at risk for vascular brain injury before the insidious onset of cognitive decline,” Kern said. “As a simple blood test, such a tool would be valuable not only for patients and clinicians, but also for researchers identifying patients for clinical trials.”
The MarkVCID consortium,which aims to validate CSVD biomarkers,conducted the study. Participants, aged 55 and older, underwent brain MRIs and blood tests to measure PlGF levels.
While the study’s design and diverse sample size support PlGF’s potential as a biomarker for vascular contributions to cognitive impairment, the authors emphasize the need for further longitudinal studies. These studies should focus on causation and timing among PlGF, FW, WMH, and cognition. Ideally, PlGF could screen younger individuals, allowing for early interventions to prevent or reverse vascular injury before cognitive dysfunction sets in. The research group is actively recruiting patients for future studies.
What’s next
Future research will focus on longitudinal studies to confirm the causal relationship between PlGF levels and cognitive decline, possibly leading to earlier interventions and preventative measures.